Discontinuation of aromatase inhibitors associated with higher copayments

[News]

Discontinuation and nonadherence were higher among breast cancer patients taking brand name aromatase inhibitors (BAIs) vs generic AIs (GAIs), according to a new study published in the JNCI: Journal...

More... (http://www.medicalnewstoday.com/releases/284505.php)